HIGHLIGHTS
We describe the experience of our hospital, UMAE 25 IMSS in Monterrey
NL, Mexico, of 11 years performing hematopoietic stem-cell
transplantation (HSCT) in pediatric patients with primary immune
deficiencies.
We report the clinical features, origin, diagnoses, treatment and
outcome of 19 patients with 8 PID diagnoses who underwent HSCT, with a
79% survival rate, 21% GVHD prevalence, 47% stable chimerism, and
58% of complete immune reconstitution.
Post-transplant cyclophosphamide has been proven effective as anti-GVHD
prophylaxis. Despite all our grafts coming from umbilical cord and
haploidentical donors, we were able to prevent GVHD by using
post-transplant cyclophosphamide.
In Mexico and Latin America, we need better local and regional donor
registries. We can achieve encouraging positive results despite resource
scarcity and other regional limitations.